Welcome to our dedicated page for Aclaris Therapeutics SEC filings (Ticker: ACRS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Aclaris Therapeutics, Inc. (ACRS) SEC filings page on Stock Titan provides access to the company’s public filings with the U.S. Securities and Exchange Commission, including current reports on Form 8-K and other key documents referenced in its investor communications. Aclaris is a Delaware-incorporated, Nasdaq-listed clinical-stage biopharmaceutical company, and its common stock is registered under Section 12(b) of the Securities Exchange Act of 1934.
For ACRS, SEC filings are an important source of information on financial results, clinical development progress, and corporate presentations. Recent Forms 8-K have furnished press releases announcing quarterly and year-to-date financial results, described as including revenue from contract research and licensing, research and development expenses tied to product candidates such as bosakitug, ATI-052 and ATI-2138, and general and administrative costs. Other 8-K filings have furnished R&D Day and corporate overview presentations and detailed top line results from the Phase 2a trial of ATI-2138 in atopic dermatitis.
Through this page, users can locate Aclaris’ current reports that summarize material events, such as updates to its clinical pipeline, conference calls discussing top line clinical data, and investor presentations. While the examples provided are 8-K filings, the SEC Filings page is also the natural place to look for Aclaris’ annual reports on Form 10-K, quarterly reports on Form 10-Q, and any proxy statements or registration statements the company files, which together outline its risk factors, business description, and governance structure.
Stock Titan enhances these filings with AI-powered tools that can help explain complex financial and scientific disclosures in plain language. For ACRS, this can be particularly useful when reviewing detailed discussions of its immuno-inflammatory pipeline, revenue components such as licensing and contract research, and non-cash items like royalty income and contingent consideration revaluations. The page also provides a path to monitor any future insider transaction reports on Form 4 or other ownership-related filings that may be associated with Aclaris’ executive officers and directors.
Aclaris Therapeutics reported that on March 10, 2026 it sold 5.7 million shares of its common stock, generating $20.0 million in aggregate gross proceeds. The sale was made under its amended and restated sales agreement with Leerink Partners LLC and Cantor Fitzgerald & Co.
The agents informed the company that the shares were purchased by Frazier Life Sciences, Kalehua Capital and Adage Capital Partners LP. The disclosure is furnished under Regulation FD and is not treated as filed for liability purposes under the Exchange Act.
Aclaris Therapeutics, Inc. reported that from March 2–9, 2026 it sold 12.7 million shares of its common stock through its amended and restated sales agreement with Leerink Partners LLC and Cantor Fitzgerald & Co.
These sales generated aggregate gross proceeds of $39.8 million and the shares were purchased by institutional investors, including Deep Track Capital. The disclosure is provided under Regulation FD and is expressly not deemed filed for liability purposes under Section 18 of the Exchange Act.
Aclaris Therapeutics Chief Financial Officer Kevin Balthaser reported equity compensation-related transactions on March 1, 2026. He exercised 2,375 Restricted Stock Units, which converted into 2,375 shares of common stock at a price of $0.0000 per share. Each restricted stock unit represents a contingent right to receive one share of common stock of the company.
To cover tax withholding obligations tied to the vesting and settlement of these units, 677 shares of common stock were withheld and disposed of at $2.87 per share, as indicated by transaction code F for tax-withholding disposition. After these transactions, Balthaser directly owned 187,453 shares of common stock.
Aclaris Therapeutics files its annual report describing a broad immuno-inflammatory pipeline and ongoing operating losses. The company is developing bosakitug and ATI-052 (anti-TSLP–based antibodies) plus oral ITK/JAK3 and ITK inhibitors for atopic dermatitis, asthma and other T cell–mediated diseases, alongside earlier-stage KINect discovery programs.
Aclaris reported net losses of $64.9 million in 2025 and $132.1 million in 2024, with an accumulated deficit of $967.8 million, funded mainly through equity and non-dilutive financing. Cash, cash equivalents and marketable securities totaled $151.4 million as of December 31, 2025, which management believes will fund operations for more than 12 months.
Aclaris Therapeutics reported fourth quarter and full-year 2025 results and highlighted progress across its immuno-inflammatory pipeline. Net loss narrowed to
Total revenue was
Cash, cash equivalents and marketable securities were
Aclaris Therapeutics, Inc. received an updated ownership report showing that BML Investment Partners, L.P. beneficially owns 14,250,000 shares of its common stock, representing 11.9% of the class as of 12/31/2025.
BML reports shared power to vote and dispose of all these shares, with no sole voting or dispositive power. The filing states the securities were not acquired or held for the purpose of changing or influencing control of Aclaris.
Aclaris Therapeutics CEO and director Walker Neal reported new equity awards granted on February 2, 2026. He received 274,800 restricted stock units, each representing the right to receive one share of common stock, and an employee stock option covering 961,700 shares of common stock.
The restricted stock units vest in four equal installments on the first, second, third, and fourth anniversaries of February 2, 2026, contingent on his continued service. The stock option, with a $3.61 exercise price per share, is exercisable as it vests over the same four-year schedule, also subject to continuous service.
Aclaris Therapeutics reported new equity awards to President and COO Hugh M. Davis, who also serves as a director. On February 2, 2026, he received 96,100 restricted stock units, each representing one share of common stock, and 336,300 employee stock options with a $3.61 exercise price.
The restricted stock units vest in four equal annual installments on the first through fourth anniversaries of February 2, 2026, contingent on his continuous service. The stock options become exercisable as 25% of the shares vest in four equal annual installments on the same anniversary dates, also subject to continuous service.
Aclaris Therapeutics reported an equity compensation grant to its Chief Scientific Officer, Roland Wilhelm Kolbeck, effective February 2, 2026. He received 95,700 restricted stock units, each representing one share of common stock, and an option to purchase 334,900 shares of common stock at an exercise price of $3.61 per share.
The restricted stock units vest in four equal installments on the first through fourth anniversaries of February 2, 2026, conditioned on his continued service. The stock option becomes exercisable as to 25% of the shares on each of the first, second, third, and fourth anniversaries of February 2, 2026, also subject to continuous service.
Aclaris Therapeutics granted its Chief Medical Officer, Jesse Wayne Hall, new equity awards on February 2, 2026. The awards consist of 98,100 restricted stock units, each representing one share of common stock, and an option to purchase 343,300 shares of common stock at an exercise price of $3.61 per share.
Both the restricted stock units and the stock options vest in four equal annual installments on the first, second, third and fourth anniversaries of February 2, 2026, conditioned on Hall’s continued service with the company. Following these grants, Hall directly holds the full reported amounts of these derivative securities.